NIH Clinical Center Search the Studies: Study Number, Study Title

Protocol Details

Observational Study Investigating the Mechanistic Effects of Mitapivat in Subjects with Sickle Cell Disease

This study is currently recruiting participants.

Summary | Eligibility | Citations | Contacts

Summary

Number

001061-H

Sponsoring Institute

National Heart, Lung and Blood Institute (NHLBI)

Recruitment Detail

Type: Enrolling by Invitation
Gender: Male & Female
Min Age: 16 Years
Max Age: N/A

Referral Letter Required

No

Population Exclusion(s)

None

Keywords

Sickle Cell Pain Crisis;
Sickle Cell Anemia;
Sickle Cell Treatment;
Sickle Cell Therapy;
Hemoglobin;
Natural History

Recruitment Keyword(s)

None

Condition(s)

Sickle Cell Anemia;
Sickle Cell Thalassemia;
Sickle Cell Pain;
Hbss;
Hbsc;
Sickle Beta Thalassemia;
Sickle Beta Zero Thalassemia;
Sickle Cell Syndrome Variant

Investigational Drug(s)

mitapivat

Investigational Device(s)

None

Intervention(s)

None

Supporting Site

National Heart, Lung, and Blood Institute

Background:

Sickle cell disease (SCD) is an inherited blood disorder. The disease affects the ability of red blood cells to carry oxygen; this in turn can injure organs including the heart, lungs, and kidneys. SCD can lead to serious illness and death. Treatments such as bone marrow transplants and gene therapies can cure SCD, but they are not widely available. Current drug treatments for SCD are not always effective. This natural history study will examine how a study drug (mitapivat) affects red blood cells in people with SCD.

Objective:

To learn how mitapivat affects red blood cells in people with SCD.

Eligibility:

People with SCD who are enrolled in the parent study, NIH protocol IRB001565-H.

Design:

Procedures for this study will be done during visits already scheduled for the parent study.

Participants will have additional blood drawn during study visits. The additional amount will be about 3.5 teaspoons.

Participants will undergo a test called near infrared spectroscopy (NIRS) up to 9 times. Probes will be placed on their skin. A blood pressure cuff will be placed on their arm. The cuff will be filled with air for up to 5 minutes and then released. Participants may be asked to breathe at a certain rate or to hold their breath during these measurements. NIRS measures oxygen levels, blood flow, and the makeup of skin and muscle.

Researchers will draw additional information for this study from participants medical records.

--Back to Top--

Eligibility

INCLUSION CRITERIA:

All subjects enrolled at NIH meeting eligibility for the parent study (AG348-C-020) are eligible for this study.

EXCLUSION CRITERIA:

Subjects that did not meet eligibility criteria to the parent protocol (AG348-C-020) will not be eligible to enroll for this study.

Subjects will be screened for implanted metal objects or devices that may be incompatible with MRI (i.e. cerebral aneurysm clip, cochlear implant, pacemaker, etc.) These subjects will be eligible to proceed with study enrollment, but will not undergo the optional MRI study.


--Back to Top--

Citations:

Not Provided

--Back to Top--

Contacts:

Principal Investigator

Referral Contact

For more information:

Swee Lay Thein, M.D.
National Heart, Lung and Blood Institute (NHLBI)
NIHBC 10 - CLINICAL CENTER BG RM 6S241A
10 CENTER DR
BETHESDA MD 20892
(301) 435-2345
sweelay.thein@nih.gov

Ingrid C. Frey
National Heart, Lung and Blood Institute (NHLBI)
BG 10-CRC RM 5-1424
10 CENTER DR
BETHESDA MD 20814
(301) 221-3820
ingrid.frey@nih.gov

Office of Patient Recruitment
National Institutes of Health Clinical Center (CC)
Building 61, 10 Cloister Court
Bethesda, Maryland 20892
Toll Free: 1-800-411-1222
Local Phone: 301-451-4383
TTY: TTY Users Dial 7-1-1
ccopr@nih.gov

Clinical Trials Number:

NCT05675436

--Back to Top--